XLRN Soars, FDA Approves Triple Combo Pill For Type 2 Diabetes, MGEN On Watch

(RTTNews) - Today's Daily Dose brings you news about Acceleron Pharma's pulmonary arterial hypertension trial data; FDA approval of Lilly's combination tablet containing three type 2 diabetes medicines in one pill; Merck's DIFICID tablets and oral suspension securing the regulatory nod in the U.S. and miRagen's near-term catalyst.

Read ona?¦

Shares of Acceleron Pharma Inc. (XLRN) were up over 60% in extended trading on Monday, following positive results from a phase II trial of Sotatercept in patients with pulmonary arterial hypertension.

The phase II trial, dubbed PULSAR, achieved its primary endpoint of a statistically significant reduction in pulmonary vascular resistance.

The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including amino-terminal brain natriuretic propeptide (NT-proBNP), and World Health Organization (WHO) functional class.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »